middle.news
Alterity Advances ATH434 Phase 3 Program with FDA Alignment and New Clinical Data
10:36am on Thursday 30th of April, 2026 AEST
•
Biotechnology
Read Story
Alterity Advances ATH434 Phase 3 Program with FDA Alignment and New Clinical Data
10:36am on Thursday 30th of April, 2026 AEST
Key Points
FDA endorses clinical pharmacology and CMC plans
Phase 2 data shows ATH434 slows MSA progression
New Chief Medical Advisor and Board appointment
Cash reserves at A$44.53 million support runway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE